Wockhardt informs about press release

27 Jan 2026 Evaluate
Pursuant to Regulation 30 of Listing Regulations, Wockhardt has informed that it enclosed Press Release – ‘Wockhardt’s Fifth Novel Antibiotic, Foviscu® (WCK 4282), Matches Gold-Standard Meropenem in pivotal Phase 3 Trial as First-Line Therapies Fail Against Rising Resistance’. A copy of the same will also be uploaded on the Company’s website www.wockhardt.com.

The above information is a part of company’s filings submitted to BSE.

Wockhardt Share Price

1356.95 8.75 (0.65%)
28-Jan-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1610.15
Dr. Reddys Lab 1224.30
Cipla 1328.25
Zydus Lifesciences 896.60
Lupin 2121.65
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×